vs
Side-by-side financial comparison of Core Scientific, Inc. (CORZ) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $79.8M, roughly 1.1× Core Scientific, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -16.0%). IOVANCE BIOTHERAPEUTICS, INC. produced more free cash flow last quarter ($-61.9M vs $-450.8M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -33.3%).
Core Scientific is a leading digital asset and high-performance computing infrastructure provider. It operates large energy-efficient data centers across North America, offering cryptocurrency mining services, colocation hosting for blockchain and AI clients, and custom high-performance computing solutions for enterprise tech segments.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CORZ vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.8M | $86.8M |
| Net Profit | $214.2M | — |
| Gross Margin | 26.0% | 67.4% |
| Operating Margin | -149.5% | -84.7% |
| Net Margin | 268.5% | — |
| Revenue YoY | -16.0% | 17.7% |
| Net Profit YoY | 180.6% | — |
| EPS (diluted) | $-1.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.8M | $86.8M | ||
| Q3 25 | $81.1M | $67.5M | ||
| Q2 25 | $78.6M | $60.0M | ||
| Q1 25 | $79.5M | $49.3M | ||
| Q4 24 | $94.9M | $73.7M | ||
| Q3 24 | $95.4M | $58.6M | ||
| Q2 24 | $141.1M | $31.1M | ||
| Q1 24 | $179.3M | $715.0K |
| Q4 25 | $214.2M | — | ||
| Q3 25 | $-144.0M | $-91.3M | ||
| Q2 25 | $-936.8M | $-111.7M | ||
| Q1 25 | $576.3M | $-116.2M | ||
| Q4 24 | $-265.5M | — | ||
| Q3 24 | $-455.3M | $-83.5M | ||
| Q2 24 | $-902.2M | $-97.1M | ||
| Q1 24 | $210.7M | $-113.0M |
| Q4 25 | 26.0% | 67.4% | ||
| Q3 25 | 4.8% | 43.0% | ||
| Q2 25 | 6.4% | 5.5% | ||
| Q1 25 | 10.3% | -0.8% | ||
| Q4 24 | 5.0% | 68.7% | ||
| Q3 24 | -0.2% | 46.2% | ||
| Q2 24 | 27.5% | -0.8% | ||
| Q1 24 | 43.3% | — |
| Q4 25 | -149.5% | -84.7% | ||
| Q3 25 | -67.6% | -140.7% | ||
| Q2 25 | -33.4% | -189.8% | ||
| Q1 25 | -59.1% | -245.8% | ||
| Q4 24 | -41.9% | -117.5% | ||
| Q3 24 | -43.2% | -152.1% | ||
| Q2 24 | -64.3% | -327.6% | ||
| Q1 24 | 30.8% | -16464.6% |
| Q4 25 | 268.5% | — | ||
| Q3 25 | -177.6% | -135.3% | ||
| Q2 25 | -1191.4% | -186.2% | ||
| Q1 25 | 724.6% | -235.5% | ||
| Q4 24 | -279.7% | — | ||
| Q3 24 | -477.4% | -142.7% | ||
| Q2 24 | -639.4% | -312.2% | ||
| Q1 24 | 117.5% | -15800.8% |
| Q4 25 | $-1.63 | — | ||
| Q3 25 | $-0.45 | — | ||
| Q2 25 | $-0.04 | $-0.33 | ||
| Q1 25 | $1.24 | $-0.36 | ||
| Q4 24 | $0.51 | $-0.24 | ||
| Q3 24 | $-1.17 | $-0.28 | ||
| Q2 24 | $-5.05 | $-0.34 | ||
| Q1 24 | $0.78 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $311.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-962.7M | $698.6M |
| Total Assets | $2.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $311.4M | $297.0M | ||
| Q3 25 | $453.4M | $300.8M | ||
| Q2 25 | $581.3M | $301.2M | ||
| Q1 25 | $697.9M | $359.7M | ||
| Q4 24 | $836.2M | $323.8M | ||
| Q3 24 | $253.0M | $397.5M | ||
| Q2 24 | $96.1M | $412.5M | ||
| Q1 24 | $98.1M | $356.2M |
| Q4 25 | $-962.7M | $698.6M | ||
| Q3 25 | $-1.3B | $702.3M | ||
| Q2 25 | $-1.2B | $698.5M | ||
| Q1 25 | $-308.8M | $767.9M | ||
| Q4 24 | $-943.0M | $710.4M | ||
| Q3 24 | $-826.7M | $773.5M | ||
| Q2 24 | $-1.2B | $768.5M | ||
| Q1 24 | $-318.5M | $680.0M |
| Q4 25 | $2.3B | $913.2M | ||
| Q3 25 | $2.2B | $904.9M | ||
| Q2 25 | $1.9B | $907.4M | ||
| Q1 25 | $1.5B | $966.7M | ||
| Q4 24 | $1.5B | $910.4M | ||
| Q3 24 | $824.6M | $991.1M | ||
| Q2 24 | $664.2M | $964.3M | ||
| Q1 24 | $814.0M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.3M | $-52.6M |
| Free Cash FlowOCF − Capex | $-450.8M | $-61.9M |
| FCF MarginFCF / Revenue | -565.1% | -71.3% |
| Capex IntensityCapex / Revenue | 914.0% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.30× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-779.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.3M | $-52.6M | ||
| Q3 25 | $131.8M | $-78.7M | ||
| Q2 25 | $34.0M | $-67.4M | ||
| Q1 25 | $-45.0M | $-103.7M | ||
| Q4 24 | $42.9M | $-73.3M | ||
| Q3 24 | $5.7M | $-59.0M | ||
| Q2 24 | $1.2M | $-98.4M | ||
| Q1 24 | $22.2M | $-122.3M |
| Q4 25 | $-450.8M | $-61.9M | ||
| Q3 25 | $-112.7M | $-89.5M | ||
| Q2 25 | $-87.3M | $-74.9M | ||
| Q1 25 | $-129.0M | $-109.9M | ||
| Q4 24 | $-52.1M | $-77.5M | ||
| Q3 24 | $-25.5M | $-61.3M | ||
| Q2 24 | $-1.9M | $-98.9M | ||
| Q1 24 | $-9.7M | $-126.5M |
| Q4 25 | -565.1% | -71.3% | ||
| Q3 25 | -139.0% | -132.7% | ||
| Q2 25 | -111.0% | -124.9% | ||
| Q1 25 | -162.2% | -222.8% | ||
| Q4 24 | -54.8% | -105.1% | ||
| Q3 24 | -26.7% | -104.6% | ||
| Q2 24 | -1.4% | -317.9% | ||
| Q1 24 | -5.4% | -17685.3% |
| Q4 25 | 914.0% | 10.7% | ||
| Q3 25 | 301.5% | 16.1% | ||
| Q2 25 | 154.2% | 12.4% | ||
| Q1 25 | 105.6% | 12.6% | ||
| Q4 24 | 100.0% | 5.7% | ||
| Q3 24 | 32.7% | 3.9% | ||
| Q2 24 | 2.2% | 1.4% | ||
| Q1 24 | 17.8% | 583.4% |
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CORZ
| Other | $36.3M | 46% |
| Digital Asset Self Mining Service | $31.8M | 40% |
| Colocation Service | $11.6M | 15% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
